US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apogee Therapeutics

39.72

+0.47001.20%

Post-market: 39.720.00000.00%16:05 EDT

Volume:415.25K

Turnover:16.29M

Market Cap:2.31B

PE:-12.04

High:39.93

Open:39.27

Low:38.25

Close:39.25

Loading ...

Overview Company News Filings

Earnings Flash (APGE) Apogee Therapeutics Posts Full Year 2024 Net Loss of $182.1M, vs. FactSet Est of $178.7M Loss

MT Newswires Live

Earnings Flash (APGE) Apogee Therapeutics Posts Full-Year 2024 Total Operating Expenses $216.9M

MT Newswires Live

BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial

Apogee Therapeutics Says Cash, Cash Equivalents And Marketable Securities Of $731.1M As Of December 31, 2024 Is Expected To Provide Cash Runway Into Q1 2028

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Apogee Therapeutics Inc - Apg990 Well Tolerated up to 1,200Mg Doses

THOMSON REUTERS

Apogee Therapeutics Announces Positive Interim Phase 1 Results From the Apg990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for Apg279 (Apg777 + Apg990)

THOMSON REUTERS

Apogee Therapeutics Inc - No Severe Adverse Events or Study Discontinuations for Apg990

THOMSON REUTERS

Apogee Therapeutics Inc - to Initiate Phase 1B Trial of Apg279 Against Dupixent in 2025

THOMSON REUTERS

Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?

Apogee Therapeutics to Host Conference Call to Report Interim Results From the Phase 1 Healthy Volunteer Trial for Apg990 and Provide Combination Strategy Update on March 3, 2025

THOMSON REUTERS

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Buy Rating Affirmed for Apogee Therapeutics: Promising Developments in Inflammatory Disease Treatments

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 Apex Trial of Apg777 in Patients With Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS

Apogee Therapeutics Inc - Part a 16-Week Proof-of-Concept Data Expected Mid-2025

THOMSON REUTERS

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/APGE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APGE\",,,,,undefined,":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":39.72,"timestamp":1743192000000,"preClose":39.25,"halted":0,"volume":415250,"hourTrading":{"tag":"盘后","latestPrice":39.72,"preClose":39.72,"latestTime":"16:05 EDT","volume":10914,"amount":433504.08,"timestamp":1743192308129},"delay":0,"floatShares":39037712,"shares":58087357,"eps":-3.300106,"marketStatus":"Not Yet Opened","change":0.47,"latestTime":"03-28 16:00:00 EDT","open":39.27,"high":39.93,"low":38.25,"amount":16286821.441132,"amplitude":0.042803,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.300106,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":0,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":39.25,"preHourTrading":{"tag":"盘前","latestPrice":39.27,"preClose":39.25,"latestTime":"09:28 EDT","volume":105,"amount":4125.2001,"timestamp":1743168480047},"postHourTrading":{"tag":"盘后","latestPrice":39.72,"preClose":39.72,"latestTime":"16:05 EDT","volume":10914,"amount":433504.08,"timestamp":1743192308129},"volumeRatio":0.5516013241858098,"impliedVol":1.0599,"impliedVolPercentile":0.992},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APGE\",,,,,undefined,":{"symbol":"APGE","floatShares":39037712,"roa":"-23.46%","roe":"-33.22%","lyrEps":-3.300106,"volumeRatio":0.5516013241858098,"shares":58087357,"dividePrice":0,"high":39.93,"amplitude":0.042803,"preClose":39.25,"low":38.25,"week52Low":29.1,"pbRate":"3.22","week52High":68.21,"institutionHeld":0,"latestPrice":39.72,"eps":-3.300106,"divideRate":0,"volume":415250,"delay":0,"ttmEps":-3.300106,"open":39.27,"prevYearClose":45.3,"prevWeekClose":39.84,"prevMonthClose":31.44,"prevQuarterClose":45.3,"fiveDayClose":39.84,"twentyDayClose":31.44,"sixtyDayClose":44.64},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APGE\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516684698","title":"Earnings Flash (APGE) Apogee Therapeutics Posts Full Year 2024 Net Loss of $182.1M, vs. FactSet Est of $178.7M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684698","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684698?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:15","pubTimestamp":1741000528,"startTime":"0","endTime":"0","summary":"Earnings Flash (APGE) Apogee Therapeutics Posts Full Year 2024 Net Loss of $182.1M, vs. FactSet Est of $178.7M Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APGE"],"gpt_icon":0},{"id":"2516684660","title":"Earnings Flash (APGE) Apogee Therapeutics Posts Full-Year 2024 Total Operating Expenses $216.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684660?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:15","pubTimestamp":1741000513,"startTime":"0","endTime":"0","summary":"Earnings Flash (APGE) Apogee Therapeutics Posts Full-Year 2024 Total Operating Expenses $216.9M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSS","APGE"],"gpt_icon":0},{"id":"2516001681","title":"BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516001681","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516001681?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:10","pubTimestamp":1741000231,"startTime":"0","endTime":"0","summary":"BRIEF-Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer TrialMarch 3 (Reuters) - Apogee Therapeutics APGE.O:APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516848236","title":"Apogee Therapeutics Says Cash, Cash Equivalents And Marketable Securities Of $731.1M As Of December 31, 2024 Is Expected To Provide Cash Runway Into Q1 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2516848236","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516848236?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:07","pubTimestamp":1741000067,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics Says Cash, Cash Equivalents And Marketable Securities Of $731.1M As Of December 31, 2024 Is Expected To Provide Cash Runway Into Q1 2028","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/03/44072233/apogee-therapeutics-says-cash-cash-equivalents-and-marketable-securities-of-731-1m-as-of-december","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516684183","title":"Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684183","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684183?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:05","pubTimestamp":1740999900,"startTime":"0","endTime":"0","summary":"Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035381/0/en/Apogee-Therapeutics-Provides-Pipeline-Progress-and-Reports-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU1169590202.USD","APGE","TSLP","BK4181","BK4139","BK4023","BK4218","PD","LU1169589451.USD","PRGS","LU2065732104.USD","PK"],"gpt_icon":0},{"id":"2516814196","title":"Apogee Therapeutics Inc - Apg990 Well Tolerated up to 1,200Mg Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2516814196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516814196?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516681966","title":"Apogee Therapeutics Announces Positive Interim Phase 1 Results From the Apg990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for Apg279 (Apg777 + Apg990)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516681966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516681966?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2516681494","title":"Apogee Therapeutics Inc - No Severe Adverse Events or Study Discontinuations for Apg990","url":"https://stock-news.laohu8.com/highlight/detail?id=2516681494","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516681494?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2516468144","title":"Apogee Therapeutics Inc - to Initiate Phase 1B Trial of Apg279 Against Dupixent in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516468144","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516468144?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAMCKTL:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516758551","title":"Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516758551","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516758551?lang=en_us&edition=fundamental","pubTime":"2025-03-01 22:22","pubTimestamp":1740838921,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where Apogee Therapeutics, Inc.  stands against the other small-cap stocks.The S&P 500 index has reached its all-time highs, achieving returns of over 20% for the second consecutive year post-COVID. With the index hitting all-time highs, small-cap stocks can be a good option to explore with higher growth potential in the long term.However, the Russell 2000 small-cap index returned a little over 7% in 2024 compared to the 23% returns by the S&P 500. Over the past five years , the S&P 500 has almost doubled the return of the Russell 2000 small cap, with returns of 102% against 47%, respectively.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-inc-apge-best-142201193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","APGE","TSYW.SI",".IXIC","MNQmain","BK4139","QID","NVIW.SI","SQQQ","USJW.SI","TQQQ","USAW.SI","NQmain","PSQ"],"gpt_icon":1},{"id":"2516855301","title":"Apogee Therapeutics to Host Conference Call to Report Interim Results From the Phase 1 Healthy Volunteer Trial for Apg990 and Provide Combination Strategy Update on March 3, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516855301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516855301?lang=en_us&edition=fundamental","pubTime":"2025-03-01 05:00","pubTimestamp":1740776400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUA4NDRYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2516301503","title":"Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301503","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516301503?lang=en_us&edition=fundamental","pubTime":"2025-03-01 05:00","pubTimestamp":1740776400,"startTime":"0","endTime":"0","summary":"Webcast to be held Monday, March 3rd at 8:30 a.m. ETSAN FRANCISCO and BOSTON, Feb.  28, 2025  (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company adva","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/28/3035028/0/en/Apogee-Therapeutics-to-Host-Conference-Call-to-Report-Interim-Results-from-the-Phase-1-Healthy-Volunteer-Trial-for-APG990-and-Provide-Combination-Strategy-Update-on-March-3-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4600","BK4181","BK4218","BK4023","BK4585","BK4588","BK4596","HST","STRK","BK4595","BK4139","APGE","BK4516"],"gpt_icon":1},{"id":"2510856815","title":"Buy Rating Affirmed for Apogee Therapeutics: Promising Developments in Inflammatory Disease Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2510856815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510856815?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:05","pubTimestamp":1739189159,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics (APGE) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Alex Thompson CFA. Alex Thompson CFA has given his ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-apogee-therapeutics-promising-developments-in-inflammatory-disease-treatments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-apogee-therapeutics-promising-developments-in-inflammatory-disease-treatments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"2508114797","title":"Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 Apex Trial of Apg777 in Patients With Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114797?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA4WC0ZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2508114720","title":"Apogee Therapeutics Inc - Part a 16-Week Proof-of-Concept Data Expected Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114720?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA4WC0ZN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2508114773","title":"Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114773","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114773?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled. Part A 16-week proof-of-concept data anticipated in mid-2025. APEX is a Phase 2 randomized, placebo-controlled clinical trial evaluating APG777, a novel, subcutaneous  extended half-life monoclonal antibody  targeting IL-13 – a critical cytokine in inflammation and a primary driver of AD, in patients with moderate-to-severe AD. The trial was designed to combine the typical Phase 2a and 2b portions of a clinical trial into a single protocol. Part A exceeded expected enrollment with 123 patients randomized 2:1 to APG777 versus placebo; patients assigned to APG777 received induction regimen dosing of 720mg at weeks 0 and 2, followed by 360mg at weeks 4 and 12 and the trial has greater than 90% power for the primary endpoint. Patients benefiting from treatment will continue to APG777 maintenance dosing, which will evaluate 3- or 6-month dosing. Part B is a placebo-controlled dose opt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apogee-therapeutics-announces-first-patient-120000106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","APGE"],"gpt_icon":0}],"pageSize":16,"totalPage":5,"pageCount":2,"totalSize":72}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-03","symbol":"APGE","fiscalQuarterEnding":"2024/12","expectedEps":-0.94,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-1.19},{"market":"US","date":"2024-11-12","symbol":"APGE","fiscalQuarterEnding":"2024/09","expectedEps":-0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.75,"buy":0.25,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.75,"analysts":8,"updateTime":1732593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APGE","date":"2025-03-28","current":-12.51704,"percent":0.940741,"low":-42.099968,"twenty":-27.099339,"median":-21.774807,"eighty":-15.344488,"high":-9.685159,"avg":-22.117374,"sd":7.497449,"marketCap":2279928762},"quantilePoints":[{"date":"2023-07-14","current":-14.120082,"twenty":-14.120082,"median":-14.120082,"eighty":-14.120082,"marketCap":728904256},{"date":"2023-07-21","current":-18.011929,"twenty":-18.356106,"median":-18.157543,"eighty":-18.011929,"marketCap":929808491},{"date":"2023-07-28","current":-20.899222,"twenty":-20.280785,"median":-18.735584,"eighty":-18.04723,"marketCap":1078855761},{"date":"2023-08-04","current":-20.732342,"twenty":-20.732342,"median":-20.114656,"eighty":-18.267856,"marketCap":1070241131},{"date":"2023-08-11","current":-21.547107,"twenty":-20.865853,"median":-20.262175,"eighty":-18.356106,"marketCap":1112300797},{"date":"2023-08-18","current":-23.166822,"twenty":-21.272247,"median":-20.482022,"eighty":-18.735584,"marketCap":1195913385},{"date":"2023-08-25","current":-24.246631,"twenty":-22.764347,"median":-20.836643,"eighty":-19.947026,"marketCap":1251655111},{"date":"2023-09-01","current":-16.923199,"twenty":-22.901778,"median":-20.784492,"eighty":-18.356106,"marketCap":1162468350},{"date":"2023-09-08","current":-17.424846,"twenty":-22.791833,"median":-20.482022,"eighty":-18.04017,"marketCap":1196926871},{"date":"2023-09-15","current":-15.33711,"twenty":-22.261745,"median":-20.262175,"eighty":-17.454355,"marketCap":1053518613},{"date":"2023-09-22","current":-15.742854,"twenty":-21.87694,"median":-20.07464,"eighty":-16.946806,"marketCap":1081389476},{"date":"2023-09-29","current":-15.255962,"twenty":-21.600116,"median":-18.735584,"eighty":-16.181057,"marketCap":1047944441},{"date":"2023-10-06","current":-15.816626,"twenty":-21.327219,"median":-18.248406,"eighty":-15.736952,"marketCap":1086456906},{"date":"2023-10-13","current":-14.754315,"twenty":-21.232981,"median":-18.011929,"eighty":-15.43744,"marketCap":1013485920},{"date":"2023-10-20","current":-14.732183,"twenty":-21.097514,"median":-17.509684,"eighty":-15.343012,"marketCap":1011965691},{"date":"2023-10-27","current":-11.065736,"twenty":-21.032725,"median":-17.443289,"eighty":-15.295798,"marketCap":760114440},{"date":"2023-11-03","current":-13.714136,"twenty":-20.892548,"median":-17.107628,"eighty":-15.064155,"marketCap":942035162},{"date":"2023-11-10","current":-11.751812,"twenty":-20.860011,"median":-16.901067,"eighty":-14.764643,"marketCap":807241535},{"date":"2023-11-17","current":-12.191046,"twenty":-20.815783,"median":-16.340404,"eighty":-14.242502,"marketCap":851834915},{"date":"2023-11-24","current":-12.473884,"twenty":-20.732342,"median":-15.9863,"eighty":-13.271633,"marketCap":871597891},{"date":"2023-12-01","current":-14.149156,"twenty":-20.643994,"median":-15.77974,"eighty":-12.959786,"marketCap":988655514},{"date":"2023-12-08","current":-15.76641,"twenty":-20.320051,"median":-15.713345,"eighty":-13.06857,"marketCap":1101659195},{"date":"2023-12-15","current":-16.854248,"twenty":-20.280785,"median":-15.705968,"eighty":-13.227243,"marketCap":1177670639},{"date":"2023-12-22","current":-18.52952,"twenty":-20.262175,"median":-15.76641,"eighty":-13.271633,"marketCap":1294728262},{"date":"2023-12-29","current":-21.77128,"twenty":-20.316166,"median":-15.824003,"eighty":-13.537135,"marketCap":1521242365},{"date":"2024-01-05","current":-20.48763,"twenty":-20.454114,"median":-15.9863,"eighty":-13.786432,"marketCap":1431548862},{"date":"2024-01-12","current":-23.098443,"twenty":-20.721111,"median":-16.285075,"eighty":-14.084509,"marketCap":1613976327},{"date":"2024-01-19","current":-23.34502,"twenty":-20.899222,"median":-16.57141,"eighty":-14.120082,"marketCap":1631205588},{"date":"2024-01-26","current":-26.1734,"twenty":-21.423171,"median":-16.854248,"eighty":-14.149156,"marketCap":1828835342},{"date":"2024-02-02","current":-24.650426,"twenty":-22.136094,"median":-16.901067,"eighty":-14.410237,"marketCap":1722419321},{"date":"2024-02-09","current":-26.833356,"twenty":-22.901778,"median":-17.107628,"eighty":-14.722084,"marketCap":1874948952},{"date":"2024-02-16","current":-25.919571,"twenty":-23.170966,"median":-17.443289,"eighty":-14.732183,"marketCap":1811099339},{"date":"2024-02-23","current":-25.462679,"twenty":-23.458155,"median":-17.594521,"eighty":-14.738085,"marketCap":1779174532},{"date":"2024-03-01","current":-25.252364,"twenty":-23.903055,"median":-18.011929,"eighty":-14.745463,"marketCap":1764478986},{"date":"2024-03-08","current":-39.349598,"twenty":-24.476372,"median":-18.248406,"eighty":-14.75284,"marketCap":3304775976},{"date":"2024-03-15","current":-39.31944,"twenty":-25.034796,"median":-18.52952,"eighty":-14.795627,"marketCap":3302243192},{"date":"2024-03-22","current":-40.133695,"twenty":-25.237859,"median":-19.967125,"eighty":-14.977105,"marketCap":3370628348},{"date":"2024-03-28","current":-41.080642,"twenty":-25.310382,"median":-20.039026,"eighty":-15.024319,"marketCap":3450157751},{"date":"2024-04-05","current":-35.585933,"twenty":-25.583066,"median":-20.203754,"eighty":-15.040549,"marketCap":2988684589},{"date":"2024-04-12","current":-40.39061,"twenty":-25.977589,"median":-20.297181,"eighty":-15.087984,"marketCap":3392205375},{"date":"2024-04-19","current":-33.647243,"twenty":-26.134238,"median":-20.48763,"eighty":-15.119386,"marketCap":2825863713},{"date":"2024-04-26","current":-30.802638,"twenty":-26.87687,"median":-20.704265,"eighty":-15.154157,"marketCap":2586959527},{"date":"2024-05-03","current":-35.061005,"twenty":-31.417884,"median":-20.865853,"eighty":-15.223502,"marketCap":2944598502},{"date":"2024-05-10","current":-35.544605,"twenty":-33.702281,"median":-21.144633,"eighty":-15.273667,"marketCap":2985213654},{"date":"2024-05-17","current":-30.341768,"twenty":-33.2059,"median":-21.423171,"eighty":-15.316454,"marketCap":3142011451},{"date":"2024-05-24","current":-25.989488,"twenty":-32.751748,"median":-21.791716,"eighty":-15.341537,"marketCap":2691315483},{"date":"2024-05-31","current":-26.170128,"twenty":-32.249341,"median":-22.218395,"eighty":-15.347905,"marketCap":2710021411},{"date":"2024-06-07","current":-23.773834,"twenty":-31.497141,"median":-22.764347,"eighty":-15.361417,"marketCap":2461875577},{"date":"2024-06-14","current":-24.341154,"twenty":-31.168024,"median":-22.917136,"eighty":-15.378422,"marketCap":2520623884},{"date":"2024-06-21","current":-21.479149,"twenty":-30.802638,"median":-22.901778,"eighty":-15.396128,"marketCap":2224251827},{"date":"2024-06-28","current":-22.551696,"twenty":-30.67474,"median":-22.901778,"eighty":-15.416784,"marketCap":2335318278},{"date":"2024-07-05","current":-21.168675,"twenty":-30.454668,"median":-22.551696,"eighty":-15.452028,"marketCap":2192101012},{"date":"2024-07-12","current":-25.927394,"twenty":-30.290963,"median":-22.599678,"eighty":-15.490824,"marketCap":2684885320},{"date":"2024-07-15","current":-27.107194,"twenty":-30.240158,"median":-22.64766,"eighty":-15.512581,"marketCap":2807058416},{"date":"2024-08-02","current":-25.825784,"twenty":-30.189354,"median":-22.706004,"eighty":-15.534337,"marketCap":2674363235},{"date":"2024-08-09","current":-22.78314,"twenty":-29.894686,"median":-22.901778,"eighty":-15.586554,"marketCap":2359285249},{"date":"2024-08-16","current":-22.360657,"twenty":-29.660984,"median":-22.773744,"eighty":-15.598555,"marketCap":2649402436},{"date":"2024-08-23","current":-23.604561,"twenty":-29.231009,"median":-22.862169,"eighty":-15.66023,"marketCap":2796786413},{"date":"2024-08-30","current":-24.399278,"twenty":-28.636347,"median":-22.994085,"eighty":-15.707443,"marketCap":2890948398},{"date":"2024-09-06","current":-23.811878,"twenty":-28.151516,"median":-23.098851,"eighty":-15.725149,"marketCap":2821350409},{"date":"2024-09-13","current":-24.28081,"twenty":-27.512504,"median":-23.170966,"eighty":-15.752276,"marketCap":2876911828},{"date":"2024-09-20","current":-26.136794,"twenty":-27.110581,"median":-23.268758,"eighty":-15.786496,"marketCap":3096818079},{"date":"2024-09-27","current":-28.649283,"twenty":-28.484417,"median":-23.34502,"eighty":-15.822528,"marketCap":3394510318},{"date":"2024-10-04","current":-28.061884,"twenty":-28.569318,"median":-23.434542,"eighty":-15.893348,"marketCap":3324912329},{"date":"2024-10-11","current":-26.610663,"twenty":-28.484417,"median":-23.533922,"eighty":-16.011479,"marketCap":3152964356},{"date":"2024-10-18","current":-27.755844,"twenty":-28.448831,"median":-23.612583,"eighty":-16.121447,"marketCap":3288651192},{"date":"2024-10-25","current":-25.643182,"twenty":-28.355515,"median":-23.773834,"eighty":-16.274009,"marketCap":3038332374},{"date":"2024-10-31","current":-27.099339,"twenty":-28.252419,"median":-23.811878,"eighty":-16.385155,"marketCap":3210865204},{"date":"2024-11-08","current":-28.654219,"twenty":-28.465143,"median":-23.860074,"eighty":-16.567059,"marketCap":3395095175},{"date":"2024-11-15","current":-19.789128,"twenty":-28.485404,"median":-23.853973,"eighty":-16.630879,"marketCap":2902332924},{"date":"2024-11-22","current":-16.628998,"twenty":-28.465143,"median":-23.803477,"eighty":-16.671147,"marketCap":2438858722},{"date":"2024-11-29","current":-17.517481,"twenty":-28.399895,"median":-23.76973,"eighty":-16.839744,"marketCap":2569166386},{"date":"2024-12-06","current":-18.297329,"twenty":-28.288946,"median":-23.604561,"eighty":-16.854248,"marketCap":2683541235},{"date":"2024-12-13","current":-17.195455,"twenty":-28.106309,"median":-23.497667,"eighty":-16.861788,"marketCap":2521936971},{"date":"2024-12-20","current":-18.243012,"twenty":-28.061884,"median":-23.417542,"eighty":-16.878936,"marketCap":2675574828},{"date":"2024-12-27","current":-18.305089,"twenty":-28.042139,"median":-23.34502,"eighty":-16.878936,"marketCap":2684679293},{"date":"2025-01-03","current":-18.29345,"twenty":-27.898004,"median":-23.314068,"eighty":-16.905494,"marketCap":2682972206},{"date":"2025-01-10","current":-19.092697,"twenty":-27.799282,"median":-23.175118,"eighty":-16.935003,"marketCap":2800192201},{"date":"2025-01-17","current":-14.239016,"twenty":-27.785817,"median":-23.13304,"eighty":-16.857264,"marketCap":2088336797},{"date":"2025-01-24","current":-15.60084,"twenty":-27.774326,"median":-23.084739,"eighty":-16.58873,"marketCap":2288066011},{"date":"2025-01-31","current":-16.489324,"twenty":-27.755844,"median":-22.901778,"eighty":-16.251878,"marketCap":2418373675},{"date":"2025-02-07","current":-16.155657,"twenty":-27.743997,"median":-22.822654,"eighty":-16.03771,"marketCap":2369437172},{"date":"2025-02-14","current":-14.068303,"twenty":-27.666994,"median":-22.64766,"eighty":-15.83959,"marketCap":2063299516},{"date":"2025-02-21","current":-13.17206,"twenty":-27.548527,"median":-22.532767,"eighty":-15.742854,"marketCap":1931853794},{"date":"2025-02-28","current":-11.845154,"twenty":-27.262231,"median":-22.345048,"eighty":-15.697836,"marketCap":1737245842},{"date":"2025-03-07","current":-11.30201,"twenty":-27.112839,"median":-22.212997,"eighty":-15.60472,"marketCap":2058615932},{"date":"2025-03-14","current":-12.223647,"twenty":-27.107194,"median":-21.977899,"eighty":-15.577851,"marketCap":2226488393},{"date":"2025-03-21","current":-12.874214,"twenty":-27.104275,"median":-21.832491,"eighty":-15.410728,"marketCap":2344986602},{"date":"2025-03-28","current":-12.51704,"twenty":-27.099339,"median":-21.774807,"eighty":-15.344488,"marketCap":2279928762}],"updateTime":1743393458770}}}